Surveillance Programs

FDA requires more time to finalize Heplisav-B postmarketing plan

The FDA is asking for more details about Heplisav-B's postmarketing surveillance plan, but Dynavax executives and analysts said they remain confident.

Angus Liu Aug 4, 2017 2:38pm